Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

20-07-2017 | Ovarian cancer | Article

Management of Breast Cancer Risk in Women with Ovarian Cancer and Deleterious BRCA1 or BRCA2 Mutations

Journal: Annals of Surgical Oncology

Authors: Andrea E. Wahner Hendrickson, MD, Jamie N. Bakkum-Gamez, MD, Fergus J. Couch, PhD, Karthik Ghosh, MD, Judy C. Boughey, MD

Publisher: Springer International Publishing

Login to get access

Abstract

Literature
1.
George A, Kaye S, Banerjee S. Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer. Nat Rev Clin Oncol. 2017;14(5):284–96.CrossRefPubMed
2.
National Comprehensive Cancer Network (NCCN). BRCA-related breast and/or ovarian cancer syndrome. 2017. https://​www.​nccn.​org/​professionals/​physician_​gls/​pdf/​genetics_​screening.​pdf.
3.
Febbraro T, Robison K, Wilbur JS, et al.  Adherence patterns to National Comprehensive Cancer Network (NCCN) guidelines for referral to cancer genetic professionals. Gynecol Oncol. 2015;138(1):109–14.CrossRefPubMedPubMedCentral
4.
Ricci MT, Sciallero S, Mammoliti S, Gismondi V, Franiuk M, Bruzzi P, et al. Referral of ovarian cancer patients for genetic counselling by oncologists: need for improvement. Public Health Genomics. 2015;18(4):225–32.CrossRefPubMed
5.
Swanson C, et al. Increasing genetic counseling referral rates after ovarian cancer diagnosis: improving the quality of ovarian cancer care. Gynecol Oncol. 2016;141(Suppl 1):194.CrossRef
6.
Antoniou A, Pharoah PD, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72(5):1117–30.CrossRefPubMedPubMedCentral
7.
Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92.CrossRefPubMed
8.
Gronwald J, Tung N, Foulkes WD, et al. Tamoxifen and contralateral breast cancer in BRCA1 and BRCA2 carriers: an update. Int J Cancer. 2006;118(9):2281–4.CrossRefPubMed
9.
Phillips KA, Milne RL, Rookus MA, et al. Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2013;31(25):3091–9.CrossRefPubMedPubMedCentral
10.
Peshkin BN, Isaacs C, Finch C, Kent S, Schwartz MD. Tamoxifen as chemoprevention in BRCA1 and BRCA2 mutation carriers with breast cancer: a pilot survey of physicians. J Clin Oncol. 2003;21(23):4322–8.CrossRefPubMed